4 Results for "

disuse osteoporosis

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "disuse osteoporosis" in MCE Product Catalog:

1
Pinoresinol Diglucoside
Pinoresinol Diglucoside
0 Images
1 Cited Publications
Cat. No.: HY-N0657
CAS No.: 63902-38-5
Category:  

Eucommia ulmoides Oliver Other Diseases Lignans Eucommiaceae Phenylpropanoids Plants Disease Research Fields

Target:  

Free Radical Scavengers NF-κB Keap1-Nrf2 Heme Oxygenase (HO) TGF-beta/Smad Akt mTOR PI3K

Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivity. Pinoresinol Diglucoside interacts with targets including ALB, HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and modulates pathways including PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads. Pinoresinol Diglucoside regulates osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, cardiac fibrosis, and vasorelaxation. Pinoresinol Diglucoside can be used for the research of osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer’s disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular diseases, and disuse osteoporosis .
loading...
    loading...
View All Sizes
MCB-22-174
MCB-22-174
0 Images
Cat. No.: HY-165607S
CAS No.: 3058199-58-6
MCB-22-174 is a deuterated Piezo1 agonist, with an EC50 value of 6.28 μM. MCB-22-174 remarkably activates the CaMKII/ERK signaling pathway and initiates Ca 2+ influx in rMSCs. MCB-22-174 significantly decreases the expression of chondrogenesis markers (Comp, Acan) and adipogenesis markers (Lpl, Fabp4) in MSCs. MCB-22-174 can effectively improve bone quality in hind-limb unloading (HU) model rats. MCB-22-174 can be used for the study of disuse osteoporosis (OP) .
loading...
    loading...
View All Sizes
Piezo1 agonist 1-d2
Piezo1 agonist 1-d2
0 Images
Cat. No.: HY-169332
CAS No.: 3058199-62-2
Piezo1 agonist 1-d2 is a Piezo1 agonist and osteogenesis promoter with an EC50 of 2.21 μM. Piezo1 agonist 1-d2 activates Piezo1 and induces calcium ion influx in mesenchymal stem cells. Piezo1 agonist 1-d2 activates the Erk signaling pathway and promotes osteogenesis of mesenchymal stem cells. Piezo1 agonist 1-d2 alleviates disuse osteoporosis in a hindlimb unloading rat model. Piezo1 agonist 1-d2 can be used for research on osteoporosis .
loading...
    loading...
View All Sizes
Pinoresinol Diglucoside (Standard)
Pinoresinol Diglucoside (Standard)
0 Images
Cat. No.: HY-N0657R
CAS No.: 63902-38-5
Category:  

Eucommia ulmoides Oliver Lignans Eucommiaceae Phenylpropanoids Plants

Target:  

Reference Standards NF-κB Keap1-Nrf2 Heme Oxygenase (HO) TGF-beta/Smad Akt mTOR PI3K

Pinoresinol Diglucoside (Standard) is the analytical standard of Pinoresinol Diglucoside (HY-N0657). This product is intended for research and analytical applications. Pinoresinol Diglucoside is an orally active lignan with multifunctional bioactivity. Pinoresinol Diglucoside interacts with targets including ALB, HIF1A, GSK3B, BCL2, MARK3, IL6, NF-κB p65, Nrf2, HO-1, and TLR4, and modulates pathways including PI3K-Akt, estrogen, MAPK, Rap1, AKT/mTOR/NF-κB, and TGF-β1/Smads. Pinoresinol Diglucoside regulates osteogenesis, bone resorption, oxidative stress, inflammation, apoptosis, ferroptosis, ferritinophagy, cardiac fibrosis, and vasorelaxation. Pinoresinol Diglucoside can be used for the research of osteoporosis, ischemia/reperfusion-induced brain injury, Alzheimer’s disease, myocardial ischemia-reperfusion injury, chondrodysplasia, diabetic cardiomyopathy, cardiac hypertrophy, hypertension, cisplatin-induced hearing loss, atherosclerotic cardiovascular diseases, and disuse osteoporosis.
loading...
    loading...
View All Sizes
Assay Types